Can Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution Be Used for External Ear Infection?
Yes, polymyxin B sulfate and trimethoprim ophthalmic solution can be used off-label for external ear infections, though it is not FDA-approved for otic use and has suboptimal coverage against the most common causative pathogen.
Rationale and Evidence
Microbiologic Considerations
The primary pathogens in acute otitis externa (AOE) are Pseudomonas aeruginosa (20%-60%) and Staphylococcus aureus (10%-70%), often as polymicrobial infections 1. This is the critical issue with using polymyxin B/trimethoprim ophthalmic solution:
- Polymyxin B provides excellent coverage against Pseudomonas aeruginosa 2
- Trimethoprim covers Staphylococcus aureus and S. epidermidis 2, 3
- However, clinical trial data from 1981 showed that trimethoprim-polymyxin B (TP) achieved only 60.6% success rates in treating otorrhea, compared to 88.6% with trimethoprim-sulfacetamide-polymyxin B (TSP), a statistically significant difference 4, 5
FDA Labeling and Off-Label Use
The FDA label explicitly states this is an ophthalmic solution 2. There is no FDA-approved otic indication. The formulation is designed for ocular use with:
- pH 4.0-6.2
- Osmolality 270-310 mOsm/kg
- Benzalkonium chloride 0.004% as preservative 2
Clinical Practice Guideline Perspective
The 2014 AAO-HNS guideline for acute otitis externa emphasizes:
- Topical antimicrobials are the mainstay of treatment for AOE 1
- The guideline does not specifically recommend ophthalmic preparations for otic use
- Oral antibiotics have limited utility and are usually inactive against the key pathogens 1
- When the tympanic membrane is non-intact (perforated or with tympanostomy tubes), non-ototoxic preparations should be used 1
Key Safety Concern: Ototoxicity Risk
Critical caveat: Polymyxin B can cause contact sensitivity in 13-30% of patients with chronic otitis externa 1. If the tympanic membrane is perforated or you cannot visualize it due to canal edema, using this preparation carries theoretical ototoxicity risk, though the guideline notes that "clinical experience with topical ototoxic antibiotics in patients with tympanic membrane perforation suggests that hearing loss does not occur after a single short course of therapy" 1.
Practical Algorithm for Decision-Making
Use polymyxin B/trimethoprim ophthalmic solution for external ear infection IF:
- Tympanic membrane is confirmed intact (visualized or normal tympanometry)
- Otic-specific antibiotics are unavailable or cost-prohibitive
- Patient has no history of polymyxin B sensitivity
- Duration limited to 7-10 days maximum 6
DO NOT use if:
- Tympanic membrane perforation present or suspected
- Tympanostomy tubes in place
- Cannot visualize tympanic membrane due to severe edema (use otic-approved agents with wick placement instead)
- Patient is diabetic or immunocompromised (higher risk for necrotizing otitis externa) 1
Dosing and Administration
While not FDA-approved for otic use, if used off-label:
- Apply 2-3 drops into affected ear canal 3-4 times daily
- Consider wick placement if canal edema prevents medication delivery 1
- Ensure adequate pain control with systemic analgesics 1
- Duration: 7-10 days 6
Better Alternatives
The guideline strongly favors otic-specific topical antibiotics that provide better Pseudomonas coverage:
- Fluoroquinolone otic preparations (ciprofloxacin, ofloxacin) are preferred and show superior efficacy 7, 6
- These are non-ototoxic and safe with perforated tympanic membranes 1
- Aminoglycoside preparations (though potentially ototoxic) may be more effective than trimethoprim-polymyxin combinations 4, 5
Bottom Line
While polymyxin B/trimethoprim ophthalmic solution has antimicrobial activity against common AOE pathogens and has been studied in otorrhea 4, 5, it is a suboptimal choice with only 60% efficacy compared to better alternatives. Use only when otic-specific preparations are unavailable, the tympanic membrane is confirmed intact, and treatment duration is limited. The 2014 AAO-HNS guideline recommends topical antimicrobials for AOE but does not endorse ophthalmic preparations for this indication 1.